Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/50105
DC FieldValueLanguage
dc.contributor.authorNaranjo, Antonioen_US
dc.contributor.authorLópez, Rubénen_US
dc.contributor.authorGarcía-Magallón, Blancaen_US
dc.contributor.authorCáceres, Lauraen_US
dc.contributor.authorFrancisco, Félixen_US
dc.contributor.authorJiménez-Palop, Mercedesen_US
dc.contributor.authorOjeda-Bruno, Soledaden_US
dc.contributor.otherNaranjo Hernandez, Antonio-
dc.date.accessioned2018-11-24T13:20:37Z-
dc.date.available2018-11-24T13:20:37Z-
dc.date.issued2014en_US
dc.identifier.issn0172-8172en_US
dc.identifier.urihttp://hdl.handle.net/10553/50105-
dc.description.abstractThe aim of this study was to analyze the longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica (PMR). Patients diagnosed with PMR were collected retrospectively in two rheumatology departments. In addition to demographic and diagnostic criteria, the chart review included the following information at baseline and at follow-up: doses of prednisone, prescription of calcium, vitamin D and bisphosphonates, bone mass measurement (BMD) and fragility fractures. We analyzed the percentage of patients undergoing BMD and were prescribed a bisphosphonate over the years. We evaluated 158 patients: 117 of them were women, mean age was 73 years, and they had an average follow-up of 4.8 years. 104 patients (66 %) received osteoporosis medication during the first visit, 44 of them were given bisphosphonate. During follow-up, another 30 treatments with bisphosphonate were added (46 % overall) while 37 cases (23 %) received no treatment with calcium or bisphosphonate. BMD was performed in 111 patients (69 %; 53 % of males and 76 % of females). Factors associated with the use of bisphosphonates were female sex (OR 4.4, 95 % CI 4.02-4.86), BMD (OR 2.4, 95 % CI 2.05-2.78) and commencement of treatment after the year 2005 (54 vs 37 %, OR 1.93, 95 % CI 1.60-2.26). No significant differences were found with age, initial doses of prednisone or the hospital. According to recent prevention guidelines, treatment with biphosphonate should have been administered in more than 90 % of patients. Although prophylaxis of glucocorticoid-induced osteoporosis in patients with PMR has increased in the recent years, many patients do not receive prophylaxis with bisphosphonate during the first visit.en_US
dc.languageengen_US
dc.relation.ispartofRheumatology Internationalen_US
dc.sourceRheumatology International[ISSN 0172-8172],v. 34, p. 1459-1463en_US
dc.subject32 Ciencias médicasen_US
dc.subject320509 Reumatologíaen_US
dc.subject.otherVertebral Fractureen_US
dc.subject.otherBone-Densityen_US
dc.subject.otherDouble-Blinden_US
dc.subject.otherPreventionen_US
dc.subject.otherRisedronateen_US
dc.subject.otherMulticenteren_US
dc.subject.otherAlendronateen_US
dc.subject.otherManagementen_US
dc.subject.otherCriteriaen_US
dc.subject.otherCollegeen_US
dc.titleLongitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumaticaen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s00296-014-3014-2en_US
dc.identifier.scopus84918777139-
dc.identifier.isi000342455600017-
dcterms.isPartOfRheumatology International-
dcterms.sourceRheumatology International[ISSN 0172-8172],v. 34 (10), p. 1459-1463-
dc.contributor.authorscopusid7003297397-
dc.contributor.authorscopusid56190064200-
dc.contributor.authorscopusid55649920400-
dc.contributor.authorscopusid56189466100-
dc.contributor.authorscopusid6603342951-
dc.contributor.authorscopusid6507358955-
dc.contributor.authorscopusid6602428868-
dc.description.lastpage1463en_US
dc.description.firstpage1459en_US
dc.relation.volume34en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.identifier.wosWOS:000342455600017-
dc.contributor.daisngid550893-
dc.contributor.daisngid7790298-
dc.contributor.daisngid24515938-
dc.contributor.daisngid8309387-
dc.contributor.daisngid5636869-
dc.contributor.daisngid1113798-
dc.contributor.daisngid4126681-
dc.contributor.daisngid4801071-
dc.identifier.investigatorRIDE-7910-2010-
dc.description.numberofpages5en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Naranjo, A-
dc.contributor.wosstandardWOS:Lopez, R-
dc.contributor.wosstandardWOS:Garcia-Magallon, B-
dc.contributor.wosstandardWOS:Caceres, L-
dc.contributor.wosstandardWOS:Francisco, F-
dc.contributor.wosstandardWOS:Jimenez-Palop, M-
dc.contributor.wosstandardWOS:Ojeda-Bruno, S-
dc.date.coverdateEnero 2014en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr0,651-
dc.description.jcr1,516-
dc.description.sjrqQ2-
dc.description.jcrqQ3-
dc.description.scieSCIE-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Grupo de investigaciones infecciosas, nutricionales e inflamatorias en pacientes hospitalarios / Study Group on infectious, nutritional and inflammatory diseases in hospitalized patients-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-2013-6664-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameNaranjo Hernández, Antonio-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

5
checked on Jan 29, 2023

WEB OF SCIENCETM
Citations

4
checked on Jan 29, 2023

Page view(s)

9
checked on Sep 25, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.